摘要
近年来,紫杉醇被用于晚期食管癌的化疗,其相关临床数据均证实了紫杉醇单药及其联合化疗方案治疗食管癌的有效性,并较经典的DF方案（顺铂＋5-氟尿嘧啶）好,但仍存在诸如耐药、药物不良反应等问题需要改进.紫杉醇各种新剂型的出现提高了其血药浓度,提高了疗效,减小了不良反应,且不用抗过敏处理,使用更加方便.紫杉醇的大部分新制剂的研究尚处于实验室阶段。
Recently,paclitaxel has been used as a new agent on patients with advanced esophageal cancer,and several studies have demonstrated that paclitaxel and paclitaxel-based regimens have significant activity in patients with advanced esophageal cancer and showed highly response rates than the combination of 5-fluorouracil （5-Fu） and cisplatin.However,there have been some problems which need to be solved such as drug-resistance,side effect,and so forth.The new medicament form of paclitaxel can not only depress poison without anti-allergy but also raise medicament curative effect as well as the pharmacal concentration.Although most of the research on the new medicament form of paclitaxel are still limited in the stage of laboratory,it has possessed potential advance in the treatment of advanced esophageal cancer
出处
《肿瘤研究与临床》
CAS
2011年第10期715-718,共4页
Cancer Research and Clinic
基金
安徽省自然科学基金（070413256X）
关键词
紫杉醇
食管肿瘤
治疗
Paclitaxel
Esophageal neoplasms
Therapy
